March 29, 2024 Nick Leschly Re: Amended and Restated Transitional Services AgreementTransitional Services Agreement • April 1st, 2024 • 2seventy Bio, Inc. • Pharmaceutical preparations • Massachusetts
2seventy bio, Inc. (the “Company”). This confirms that you will be transitioning from your CEO position in connection with, and conditioned on the closing of, the transactions contemplated by the Asset Purchase Agreement (the “APA”) by and between the Company and Regeneron Pharmaceuticals, Inc. (“Buyer”) (the “Transaction,” and such closing date, the “Closing Date”). This Agreement amends, restates and supersedes the Transitional Services Agreement between you and the Company, dated January 29, 2024 (the “Prior Agreement”); provided that your Ongoing Obligations (as defined below) shall remain in full effect.
